 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Telavancin.
|
| This is the talk page for discussing improvements to the Telavancin article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
Costs and sales revenue edit
What can we say about the cost of a course of telavancin, and the sales revenues since FDA approval ? - Rod57 (talk) 11:01, 4 April 2013 (UTC)
Is it still being sold ? [1] says "The drug was sold ... by Astellas Pharma Inc. until it returned the drug to Theravance in January [2012?]." - Rod57 (talk) 11:22, 4 April 2013 (UTC)
When was it first made edit
When was it made and patented. How is it synthesised ? What changes from vancomycin ? - Rod57 (talk) 13:16, 6 April 2013 (UTC)
Efficacy edit
What clinical trial results are there that show how it compares to vancomycin ? When would one use telavancin rather than vancomycin ? - Rod57 (talk) 13:43, 6 April 2013 (UTC)
Half-life in humans edit
Info box just says "9 hours" (whereas vancomycin says "Half-life : 4–11 hours (adults) 6-10 days (adults, impaired renal function)") - Does telavancin have a longer half-life than vancomycin, and is that good, or the reason for more toxicity ? - Rod57 (talk) 13:56, 6 April 2013 (UTC)